Bullous pemphigoid and diabetes mellitus: Are we missing the larger picture?

To the Editor: We read with interest the study by Benzaquen et  al1 reporting an increased risk for development of bullous pemphigoid (BP) in patients who are receiving a dipeptidyl peptidase-4 inhibitor (DPP4i). Their findings are supported by previous studies showing a significant signal of increased risk for development of BP during exposure to a DPP4i in t he European and French pharmacovigilance databases.1

Source: Journal of the American Academy of Dermatology - July 14, 2018 Category: Dermatology Authors: Shamir Geller, Noa Kremer, Tal Zeeli, Eli Sprecher Tags: JAAD Online Source Type: research